- Conditions
- Smoking Cessation
- Interventions
- Cytisine, Placebo Comparator, Behavioral support
- Drug · Behavioral
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 8
- States / cities
- Tempe, Arizona • Burbank, California • Lexington, Kentucky + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 4,513
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Dostarlimab, Belrestotug, Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Taselisib
- Other · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1106
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 688 more
- Conditions
- Bleeding Active
- Interventions
- CELSTAT, Surgicel Original
- Device
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 19
- States / cities
- Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 14 more
- Conditions
- Alzheimer's Disease
- Interventions
- LY450139, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Smoking Cessation Intervention, Health Promotion and Education, Informational Intervention, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 223
- States / cities
- Kingman, Arizona • Fort Smith, Arkansas • St. Helena, California + 186 more
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Interventions
- cholecalciferol, placebo
- Dietary Supplement · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 360
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 303
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 226 more
- Conditions
- Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Ann Arbor Stage III Childhood Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
- Interventions
- Cytology Specimen Collection Procedure
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 1,271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 165
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Eluxadoline, Placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 257
- States / cities
- Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more
- Conditions
- Low Back Pain
- Interventions
- Progressive Muscle Relaxation (PMR), Clinical Massage Therapy (CMT)
- Behavioral · Procedure
- Lead sponsor
- William G Elder JR
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Lower Back Pain
- Interventions
- Carisoprodol SR 700 mg, Carisoprodol SR 500 mg, Placebo
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Hueytown, Alabama + 62 more
- Conditions
- Cervical Cancer
- Interventions
- AGEN2034, AGEN1884
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 227
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
- Conditions
- Anterior Cruciate Ligament
- Interventions
- Gel-One, Saline Placebo
- Drug · Other
- Lead sponsor
- Cale Jacobs, PhD
- Other
- Eligibility
- 14 Years to 33 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more
- Conditions
- Multiple Sclerosis
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,487 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 140 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Oral semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 84
- States / cities
- Buena Park, California • Fresno, California • La Mesa, California + 74 more
- Conditions
- Obesity
- Interventions
- Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
- Conditions
- Opioid Use Disorder (OUD)
- Interventions
- Communities That HEAL, Wait-list control
- Other
- Lead sponsor
- RTI International
- Other
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- Lexington, Kentucky • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, Laboratory Biomarker Analysis, Palbociclib
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1065
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more
- Conditions
- Alzheimer Disease
- Interventions
- Dimebon 20 mg po TID, Placebo po TID
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Costa Mesa, California • Encino, California + 17 more
- Conditions
- Ankle Sprain
- Interventions
- Diclofenac epolamine, Placebo
- Drug · Other
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 658 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Carlsbad, California + 26 more